Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCLK1 | O15075 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 1/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 1.00 |
| ▸ | FER | P16591 | 1/20 | 1.00 |
| ▸ | CDK2 | P24941 | 1/20 | 1.00 |
| ▸ | MARK3 | P27448 | 1/20 | 1.00 |
| ▸ | FLT4 | P35916 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 1/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 1/20 | 1.00 |
| ▸ | CLK2 | P49760 | 1/20 | 1.00 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 1.00 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 1.00 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 1.00 |
| ▸ | STK3 | Q13188 | 1/20 | 1.00 |
| ▸ | CAMK2B | Q13554 | 1/20 | 1.00 |
| ▸ | CAMK2G | Q13555 | 1/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1362524 | 0.86 | CDK2 (0.75) | DCLK1PRKD3MAP4K4CHEK2CSF1R | |
| SCHEMBL2731639 | 0.86 | FLT3 (0.75) | DCLK1PRKD3MAP4K4CHEK2CSF1R | |
| SCHEMBL11686272 | 0.83 | DCLK1 (0.71) | DCLK1PRKD3MAP4K4CHEK2CSF1R | |
| SCHEMBL31210155 | 0.83 | CDK2 (0.71) | DCLK1PRKD3MAP4K4CHEK2CSF1R | |
| SCHEMBL4734012 | 0.83 | CSNK1D (0.71) | DCLK1PRKD3MAP4K4CHEK2CSF1R | |
| SCHEMBL17306449 | 0.81 | MKNK1 (0.87) | DCLK1PRKD3MAP4K4CHEK2CSF1R | |
| SCHEMBL4733514 | 0.79 | DYRK1A (0.66) | DCLK1PRKD3MAP4K4CHEK2CSF1R | |
| SCHEMBL17801064 | 0.79 | DCLK1 (0.65) | DCLK1PRKD3MAP4K4CHEK2CSF1R | |
| SCHEMBL16862707 | 0.79 | MAPK10 (0.67) | DCLK1PRKD3MAP4K4CHEK2CSF1R | |
| SCHEMBL5378056 | 0.79 | DCLK1 (0.65) | DCLK1PRKD3MAP4K4CHEK2CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115947690-B | Preparation method of indazole molecular building block and application of indazole molecular building block in drug synthesis | 安徽医科大学 | 2025-04-08 | — | — | CN | disclosed |
| CN-118878545-A | Carbazolophenazinyl-containing compound, intermediate, organic electroluminescent device and display device | 阜阳欣奕华新材料科技股份有限公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-117247392-A | Carbazolophenazinyl-containing compound, intermediate for preparing carbazolophenazinyl-containing compound and application of carbazolophenazinyl-containing compound | 阜阳欣奕华材料科技有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| CN-111868037-B | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2023-10-13 | — | — | CN | disclosed |
| CN-115947690-A | Preparation method of indazole molecular building block and application of building block in drug synthesis | 安徽医科大学 | 2023-04-11 | — | — | CN | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-03-18 | — | — | US | disclosed |
| EP-3774739-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RaQualia Pharma Inc. (JP) | 2021-02-17 | — | — | EP | disclosed |
| CN-111868037-A | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2020-10-30 | — | — | CN | disclosed |
| CN-101282972-A | Piperidine and piperazine derivatives as P2X3 antagonists | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | CN | disclosed |
| EP-1917262-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| CN-101146796-A | 3-(indazol-5-yl)-(1,2,4)triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer | SCHERING CORP (US) | 2008-03-19 | — | — | CN | disclosed |
| US-20080004257-A1 | Kinase inhibitors | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-20080004257-A1 | Kinase inhibitors | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-20080004257-A1 | Kinase inhibitors | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| EP-1871765-A2 | 3-(INDAZOL-5-YL)-(1,2,4)TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
| WO-2006081230-A2 | 3-(INDAZOL-5-YL)-(1,2, 4) TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | DCLK1 3877/4885PRKD3 1243/4885MAP4K4 2762/4885 |
| US-20080004257-A1 | Kinase inhibitors | MAP3K1, MAP3K13, MAP3K6 | DCLK1 322/4885PRKD3 171/4885MAP4K4 28/4885 |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | DCLK1 3173/4885PRKD3 1533/4885MAP4K4 2010/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | DCLK1 3173/4885PRKD3 1533/4885MAP4K4 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.